Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in 'Theranostics' and Personalized Medicine)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,995	180 Pages	Kalorama Information	June, 2008	KLI1646599

Best Price Guarantee
Price	from $2,995
Length	180 Pages
Publisher	Kalorama Information
Published Date	June, 2008
SKU	KLI1646599

Table of Contents
Description

This Kalorama Information report, Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) is truly a real-world guide to the potential market for companion diagnostics.

Essentially the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as an important growth strategy in both the diagnostic and pharmaceutical industries. It is envisioned as a pathway to personalized medicine, where the right therapeutic is selected for the right patient. Personalized medicine is one of the key trends in healthcare, and it's no surprise that there is great enthusiasm in many quarters of the in vitro industry, pharmaceutical companies and the investment community about companion diagnostics. But will the concept work in the fashion that the industry is envisioning? Who will succeed and with what strategy? How much can companies expect to earn in this field? What strategies should companies adopt to thrive in this market?

In this report, Kalorama Information analyst Kenneth Krul, PhD. brings a real-world view to the concept of companion diagnostics and the likely scenario given market conditions. He addresses the myriad challenges that diagnostic and pharmaceutical companies will face in this endeavor. He outlines strategies that will be more successful. His analysis includes:

A Complete Explanation of Companion Diagnostics
Realistic Market Forecasts for the Companion Diagnostics to 2018
A Glossary of Terms Used in this Industry
Review of Collaborations Between Pharma and Diagnostic Companies
Possible Pitfalls the Companion Diagnostic Concept will Face.
Companies Best Poised to Profit From This Market
10 Strategic Conclusions about the Market and Implications for Marketers
The Key Therapeutic Areas Where Companion Diagnostics Could Succeed.
The Best Approaches for Companion Diagnostics Marketing

As with all Kalorama Information reports, this report is the result of analysis from a professional in the industry combined with thorough research and interviews with experts. Our interview-based methodology uncovers insight about market not possible from reports based on culled information.

The following companies and their efforts in companion diagnostics are profiled in this report:

Abbott Diagnostics
Affymetrix, Inc
Agilent Technologies, Inc
Althea Technologies, Inc
Curidium Medica plc
Dako
Gen Probe
Genzyme Corporation
Ipsogen SAS
Lipomics Technologies, Inc.
Osmetech plc
Perlegen Sciences
Provista Life Sciences
Qiagen NV
Singulex, Inc.
Theranostics Health
Ventana Medical Systems

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

Background
- Potential Benefits of Companion Diagnostics
- Pitfalls of Personalized Medicine
- Scope and Methodology
- Market Factors and Estimates
- Drivers For Companion Diagnostics
- Assumptions
- Important Trends
- Possible Tactic: Royalty Model

CHAPTER TWO: OVERVIEW OF COMPANION DIAGNOSTICS

Personalized Medicine
Potential Benefits
Privacy and Public Perception
Biomarkers and Companion Diagnostics
- Types of Biomarkers

CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS

Pharmacogenetics and Pharmacogenomics
Historical Basis
Current Techniques
Requirements
Cost-effectiveness
Applications
- The Cytochrome System
- Cancer
- Amgen
- UAMS Multiple Myeloma Project
- DakoAssay for TOP2A
- GE and Eli Lilly
- Epigenomics and Abbott
- Celera and Merk
- bioMerieiux and Ipsen
- Acute Lymphoblastic Leukemia
Regulatory Agencies
Applications of Genome More Challenging Than Expected
Cardiovascular Disease
RAS polymorphisms With Drug Effectiveness
- Pgp
- Thiazide diuretics
- 825T allele
- HIT
- Statins
Psychiatry and Pharmacogenetics/Pharmacogenomics
Is Herceptin a Paradigm?
A Balancing Act Between the Players

CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS

Estimating Market Potential
Associated Testing
The Needs of Pharma and of Diagnostic Companies
Questions Determining Companion Diagnostics Growth
A Partial Change in Attitude
Intellectual Property
Cancer Market Potential Estimate
Ideal Market Potential - Cancer, Heart Disease, Psychiatric
Source: Kalorama Information
Challenges Unique to Companion Diagnostics
Privacy Concerns
Fear of Learning About Diseases
Use of Remnant Samples
Avoiding Pitfalls of Market Calculation
Companion Diagnostics Not Linked to Molecular Diagnostics
Demonic and SNP Analysis
Considering Time of Cooperative Development
Market Realities to Consider
Possible Tactic: Royalty Model

CHAPTER FIVE: COMPANY SUMMARIES

Overview
Abbott (Molecular) Diagnostics Subsidiary of Abbott Laboratories
Affymetrix, Inc.
Agilent Technologies, Inc
Althea Technologies, Inc.
Curidium Medica plc
Dako
Gen Probe
Genzyme Corporation
Ipsogen SAS
Lipomics Technologies, Inc.
Osmetech plc
Perlegen Sciences
Provista Life Sciences
Qiagen NV
Singulex, Inc.
Theranostics Health
Ventana Medical Systems

CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS

First Conclusion
Implications:
Second Conclusion
Implications:
Third Conclusion
Implications:
Fourth Conclusion
Implications:
Fifth Conclusion
Implications:
Sixth Conclusion
Implications: Seventh Conclusion Implications:
Eighth Conclusion
Implications:
Ninth Conclusion
Implications:
Tenth Conclusion
Implications:

APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
Figure 1-1: Market Projection Trends for Companion Diagnostics in the United States: 2008 - 2018

CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS

Table 3-1 Companion Diagnostics Groups
Table 3-3: Frequency of Recessive Traits
Table 3-4: Existing Cancer Drugs Complimentary to Companion Diagnostics
Table 3-5: Recent Activities in Companion Diagnostics

CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS

Table 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
Figure 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
Table 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
Figure 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
Figure 4-3: The Ideal Companion Diagnostics Market (Ideal vs. Likely to Benefit)
Figure 4-4 Subset of Ideal Market Likely to Benefit From Pharmaceutical Intervention (Likely to Benfit vs. Realistic Market)
Table 4-3: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
Figure 4-1: Market Projection Trends for Companion Diagnostics* in the United States: 2008 - 2018